Evogene Collaborations With Bayer CropScience and Monsanto

Evogene Collaborations With Bayer CropScience and Monsanto Company
Nominated for 2012 Agrow Awards 
Two Evogene Collaborations Among Four Nominations for Best Industry
Collaboration Worldwide With Winner to Be Announced in November 
REHOVOT, ISRAEL -- (Marketwire) -- 10/09/12 --  Evogene Ltd. (TASE:
EVGN), a leading developer of improved plant traits for the food,
feed and biofuel industries, announced today that its collaborations
with Bayer CropScience and Monsanto Company have received two out of
the four nominations for the 2012 Agrow Award for Best Industry
Collaboration worldwide. The final award will be presented at the
annual Agrow Awards ceremony, the most prestigious event for the crop
protection industry, next month in London.  
The collaboration with Bayer CropScience was initiated in January
2011 and constitutes a multiyear collaboration to accelerate the
development and introduction of improved wheat varieties through the
utilization of a combination of advanced breeding and state of the
art genetic modification methods. 
The collaboration with Monsanto was signed in November 2011 and is an
extension to the two companies' multiyear research and development
collaboration focused on identifying key plant genes related to
yield, environmental stress and fertilizer utilization in corn,
soybean, cotton and canola.  
Ofer Haviv, Evogene's President and CEO, stated: "As a young company
currently listed only on the Israeli Tel Aviv Stock Exchange, we are
of course very honored and pleased that the joint achievements being
accomplished in these collaborations and our rapidly growing role in
the worldwide food, feed and fuel industries are being recognized
through these two nominations." 
About the Agrow Awards 
 The 2012 Agrow Awards features 15 categories
that reward innovation and excellence in diverse areas, ranging from
product chemistry and technology, business strategy, to corporate
responsibility. The Best Industry Collaboration award recognizes a
successful partnership between two companies in the worldwide crop
protection or plant biotechnology arena. All forms of collaboration
between two parties are eligible, including R&D collaborations,
licensing agreements, joint ventures, manufacturing or formulation
arrangements, or sales, marketing or distribution collaborations.
Eligible partnerships must have been formed within the last two
years. The other two nominees in this category for 2012 are the
collaborations between Certis USA and Kumiai Chemical and between
Makhteshim Agan and ChemChina. 
About Evogene
 Evogene is a world leading developer of improved plant
traits, such as yield and drought tolerance, for a wide diversity of
key crops through the use of plant genomics. The company focuses on
utilizing its proprietary computational genomic technologies to
provide a complete solution for plant trait improvement through
combining state of the art biotechnology and advanced breeding
methods. Evogene is collaborating with world leading seed companies
to introduce its improved plant traits into key commercial crops
under milestone and royalty bearing agreements. Evogene's
headquarters are in Rehovot, Israel, and its shares are traded on the
Tel Aviv Stock Exchange (TASE: EVGN). For additional information,
please visit Evogene's website at www.evogene.com 
This press release contains "forward-looking statements" relating to
future events. These statements may be identified by words such as
"may", "expects", "intends", "anticipates", "plans", "believes",
"scheduled", "estimates" or words of similar meaning. Such statements
are based on current expectations, estimates, projections and
assumptions, describe opinions about future events, involve certain
risks and uncertainties which are difficult to predict and are not
guarantees of future performance. Therefore, actual future results,
performance or achievements of Evogene may differ materially from
what is expressed or implied by such forward-looking statements due
to a variety of factors, many of which beyond Evogene's control,
including, without limitation, those risk factors contained in
Evogene's reports filed with the Israeli Securities Authority.
Evogene disclaims any obligation or commitment to update these
forward-looking statements to reflect future events or developments
or changes in expectations, estimates, projections and assumptions. 
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2116484 
Contact Information 
Efrat Barak Zadok 
IR&PR Associate 
E-mail: efratbz@evogene.com
Tel: +972-8-931-1940  
Press spacebar to pause and continue. Press esc to stop.